Back to OPY
Sagent Pharmaceuticals to Present at Two Upcoming Financial Conferences

SCHAUMBURG, Ill., Oct. 26 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company with a focus on injectable products, today announced that Jeffery M. Yordon, chief executive officer, founder and chairman of the board of Sagent Pharmaceuticals, has accepted invitations to present at upcoming conferences sponsored by Oppenheimer & Co. Inc. and Lazard Capital Markets LLC.

On Tuesday, November 3, 2009, Mr. Yordon will present at the Oppenheimer 20th Annual Healthcare Conference at 11:25am Eastern Time. This conference, which is taking place November 3-4 at the Waldorf=Astoria Hotel in New York, NY, will feature presentations by leading public and private companies in the pharmaceutical, biotechnology, medical device, healthcare facility, health technology and distribution, provider and service industries.

Two weeks following, Mr. Yordon will present at the Lazard Capital Markets 6th Annual Healthcare Conference at 10:55am Eastern Time on Tuesday, November 17, 2009. This conference, which is being held November 17-18 at the St. Regis Hotel in New York, NY, will feature presentations from 150 leading healthcare companies, five expert panel discussions, a "Conference Top Picks" panel with Lazard Capital Markets research analysts, and Senator Tom Daschle as the keynote speaker, on "Solving the Healthcare Crisis."

About Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, founded in 2006, is a privately held specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients. Sagent currently has more than 200 products in development.

To Discover Injectables Excellence(TM) and learn more about Sagent, please visit www.SagentPharma.com.

SOURCE Sagent Pharmaceuticals, Inc.

Copyright (2009) PR Newswire. All Rights Reserved.
Back to OPY
Wikinvest © 2006, 2007, 2008, 2009. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki